Enzo Biochem Reports Delaware Court Ruling
June 29 2017 - 8:00AM
Business Wire
Enzo Biochem Inc. (NYSE:ENZ) reported today that a federal judge
for the U.S. District Court for the District of Delaware has
entered an order in the actions entitled Enzo Life Sciences, Inc.
v. Gen-Probe Incorporated, Enzo Life Sciences, Inc. v. Hologic,
Inc., Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc.,
and Enzo Life Sciences, Inc. v. Becton, Dickinson and Company,
denying summary judgment that U.S. Patent No. 6,992,180 (“the ‘180
Patent”) is invalid for lack of written description, but granting
summary judgment that the ‘180 Patent is invalid for lack of
enablement.
The ruling addresses only one patent at issue in the ongoing
patent infringement actions between Enzo and the defendants in each
case. At least one other Enzo patent remains pending against each
defendant in those or parallel actions. Enzo believes that the
Court’s ruling was in error, and is exploring options for review of
the decision.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Except for historical information, the matters discussed in this
news release may be considered "forward-looking" statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements include declarations regarding the intent,
belief or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2016. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170629005369/en/
For: Enzo Biochem, Inc.Steve Anreder,
212-532-3232steven.anreder@anreder.comorCEOcast, Inc.Michael Wachs,
212-732-4300mwachs@ceocast.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Sep 2023 to Sep 2024